^
Association details:
| Biomarker: | SF3B1 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS)
Published date:
01/07/2022
Excerpt:
The mOS was 73.3 months but only 25.6 months after patients stopped lenalidomide...SF3B1 mutations had a significantly shorter mOS...Multivariate analysis confirmed lenalidomide response and SF3B1 mutations are independently associated with outcomes.
DOI:
https://doi.org/10.1016/j.clml.2022.01.002
